Continuation and maintenance use of antidepressants in recurrent depression. 2008

Claudi L H Bockting, and Mascha C ten Doesschate, and Jan Spijker, and Philip Spinhoven, and Maarten W J Koeter, and Aart H Schene, and
Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. c.l.h.bockting@rug.nl

BACKGROUND Maintenance antidepressant (AD) medication is the most commonly used preventive strategy in a highly recurrent disease, i.e. depression. Little is known about the discontinuation of maintenance AD use and the association with recurrence in daily clinical practice. The purpose was to examine the discontinuation rate of maintenance AD in daily clinical practice in recurrently depressed patients and the associated risk of recurrence. METHODS Prospectively AD maintenance medication and recurrence were examined in 172 euthymic patients with recurrent depression. AD user profiles before recurrence (nonusers, intermittent users, continuous users) were examined and related to recurrence over a 2-year follow-up period. RESULTS Less than half of the patients (42%) used AD continuously. Taking into account the minimal required adequate used dosage (> or = 20 mg fluoxetine equivalent), only 26% of the patients used AD as recommended by international guidelines. Despite continuous use of AD, 60.4% relapsed in 2 years. This relapse rate was comparable to the rate of the intermittent users (63.6%). In patients who stopped taking AD after remission and who received additional preventive CT, the recurrence rates were significantly lower than in non-AD-using patients treated with usual care (8 vs. 46%). CONCLUSIONS The majority of recurrently depressed patients treated with AD discontinue maintenance AD therapy in daily primary and secondary clinical practice. AD seems to offer poor protection against relapse in this patient group. Patients who stopped using AD experienced less relapse, especially if they were treated with preventive CT. Alternative maintenance treatments (including preventive cognitive therapy after discontinuation of AD) should be studied in recurrently depressed patients with intermittent good remission, not only in secondary but also in primary care.

UI MeSH Term Description Entries
D008134 Long-Term Care Care over an extended period, usually for a chronic condition or disability, requiring periodic, intermittent, or continuous care. Care, Long-Term,Long Term Care
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D010352 Patient Dropouts Discontinuance of care received by patient(s) due to reasons other than full recovery from the disease. Dropout, Patient,Dropouts, Patient,Patient Dropout
D010554 Personality Disorders A major deviation from normal patterns of behavior. Avoidant Personality Disorder,Impulse-Ridden Personality,Inadequate Personality,Avoidant Personality Disorders,Impulse Ridden Personality,Personality Disorder,Personality Disorder, Avoidant,Personality Disorders, Avoidant,Personality, Impulse-Ridden,Personality, Inadequate
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003865 Depressive Disorder, Major Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5) Depression, Involutional,Major Depressive Disorder,Melancholia, Involutional,Paraphrenia, Involutional,Psychosis, Involutional,Depressive Disorders, Major,Involutional Depression,Involutional Melancholia,Involutional Paraphrenia,Involutional Paraphrenias,Involutional Psychoses,Involutional Psychosis,Major Depressive Disorders,Paraphrenias, Involutional,Psychoses, Involutional
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

Claudi L H Bockting, and Mascha C ten Doesschate, and Jan Spijker, and Philip Spinhoven, and Maarten W J Koeter, and Aart H Schene, and
January 2001, British medical bulletin,
Claudi L H Bockting, and Mascha C ten Doesschate, and Jan Spijker, and Philip Spinhoven, and Maarten W J Koeter, and Aart H Schene, and
December 1981, Psychosomatics,
Claudi L H Bockting, and Mascha C ten Doesschate, and Jan Spijker, and Philip Spinhoven, and Maarten W J Koeter, and Aart H Schene, and
April 2008, The American journal of psychiatry,
Claudi L H Bockting, and Mascha C ten Doesschate, and Jan Spijker, and Philip Spinhoven, and Maarten W J Koeter, and Aart H Schene, and
September 2007, Nihon rinsho. Japanese journal of clinical medicine,
Claudi L H Bockting, and Mascha C ten Doesschate, and Jan Spijker, and Philip Spinhoven, and Maarten W J Koeter, and Aart H Schene, and
April 2019, Issues in mental health nursing,
Claudi L H Bockting, and Mascha C ten Doesschate, and Jan Spijker, and Philip Spinhoven, and Maarten W J Koeter, and Aart H Schene, and
November 2012, The Cochrane database of systematic reviews,
Claudi L H Bockting, and Mascha C ten Doesschate, and Jan Spijker, and Philip Spinhoven, and Maarten W J Koeter, and Aart H Schene, and
September 2016, The Cochrane database of systematic reviews,
Claudi L H Bockting, and Mascha C ten Doesschate, and Jan Spijker, and Philip Spinhoven, and Maarten W J Koeter, and Aart H Schene, and
June 2011, The journal of ECT,
Claudi L H Bockting, and Mascha C ten Doesschate, and Jan Spijker, and Philip Spinhoven, and Maarten W J Koeter, and Aart H Schene, and
March 2008, Journal of psychopharmacology (Oxford, England),
Claudi L H Bockting, and Mascha C ten Doesschate, and Jan Spijker, and Philip Spinhoven, and Maarten W J Koeter, and Aart H Schene, and
August 2009, Evidence-based mental health,
Copied contents to your clipboard!